1.80
-0.04 (-2.17%)
| Previous Close | 1.84 |
| Open | 1.84 |
| Volume | 560,682 |
| Avg. Volume (3M) | 858,767 |
| Market Cap | 231,614,176 |
| Price / Sales | 0.500 |
| Price / Book | 1.51 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2026 |
| Profit Margin | -3.46% |
| Operating Margin (TTM) | -23.28% |
| Diluted EPS (TTM) | -0.160 |
| Quarterly Revenue Growth (YOY) | -21.20% |
| Quarterly Earnings Growth (YOY) | 289.40% |
| Total Debt/Equity (MRQ) | 11.58% |
| Current Ratio (MRQ) | 4.12 |
| Operating Cash Flow (TTM) | 4.43 M |
| Levered Free Cash Flow (TTM) | -4.36 M |
| Return on Assets (TTM) | 0.70% |
| Return on Equity (TTM) | -4.92% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Bullish | |
| Stock | Organogenesis Holdings Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.86 |
|
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 46.49% |
| % Held by Institutions | 54.09% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |